According to a report by Menafn on October 16th, biotechnology company 22nd Century Group has announced plans to publicly offer the sale of its common stock or alternative equivalents, as well as subscription warrants to purchase common stock. All common stock or equivalents, as well as subscription warrants, to be sold in the offering will be issued by 22nd Century Group.
Dawson James Securities has been appointed as the exclusive underwriter for this public offering. The company anticipates utilizing the net proceeds from this issuance for general corporate purposes.
According to reports, 22nd Century Group is a leading biotechnology company dedicated to improving health through advanced plant technologies utilizing reduced nicotine tobacco, cannabis/hemp, and hops. The company secured the first and only Modified Risk Tobacco Product (MRTP) authorization from the US Food and Drug Administration in December 2021 for its tobacco combustion product.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
